Other Learning Activities

Watch Full Webinar

Speakers:

• Vivien Brown, MDCM, CCFP, FCFP, NCMP
  Assistant Professor Department of Family & Community Medicine University of Toronto
• John Papastergiou, BScPhm, PhDc
  Pharmacist/Owner & Assistant Professor Leslie Dan Faculty of Pharmacy, University of Toronto School of Pharmacy, University of Waterloo

Additional resources:

• Request slide decks via email (health-care professionals only)
• Evaluation survey

This webinar will help learners understand the landscape and burden of HPV-related head and neck cancer among Canadians. The session will explore the community pharmacist’s role in prevention by integrating a sustainable immunization program into a busy community pharmacy practice. The speakers will review vaccination and access to care opportunities created during the global pandemic and discuss strategies for alleviating some of these pressures. Overcoming barriers to implementation will also be discussed and best practices for prevention will be shared.

Watch Full Webinar

Speaker:

• Michael Boivin, BSc. Phm, RPh, CDE, CTE
  Clinical pharmacist consultant and president, CommPharm Consulting Inc.
• Jen Belcher, Hon BSc, BSc Phm, MBA
  Vice president, strategic initiatives & member relations, Ontario Pharmacists Association

Additional resources:

• Slide deck

Every year, community-acquired pneumonia is associated with significant morbidity and mortality. Many patients are concerned about their risk of pneumonia but are unaware of the different vaccine options that have been shown to lower their risk. This webinar will review the impact of pneumococcal disease and the new vaccine options for at-risk patients. Attendees will leave this session with an understanding of who is a candidate for pneumococcal vaccines, as well as oral antiviral therapy once infected with Covid-19 and practical tips to discuss these options with their patients.

Watch Full Webinar

Speaker:

• Michael Boivin, BSc. Phm, RPh, CDE, CTE
  Clinical pharmacist consultant and president, CommPharm Consulting Inc.
• Dr. Brian Conway, MD, FRCPC
  President and medical director, Vancouver Infectious Diseases Centre

Additional resources:

• Slide deck
• Evaluation survey
• Additional information & resources

COVID-19 vaccines have been foundational in reducing the number of infections and severe outcomes associated with SARS-CoV2 infections. Unfortunately, a portion of individuals with immunocompromising conditions do not respond to these COVID-19 vaccines as well as healthy individuals. As public health measures (e.g., masking, physical distancing) are being removed across the country, patients with a lower immune response to vaccines are at elevated risk of infections and severe COVID-19 outcomes. Tixagevimab/Cilgavimab is a monoclonal antibody treatment that has been approved to be used to prevent COVID-19 infections in patients who are unable to mount an adequate immune response to COVID-19 vaccinations. This webinar will review the practical role of this treatment option to prevent COVID-19 in these patients at risk. This learning activity may be of interest to both community & hospital pharmacists, those supporting heme-oncology, transplant, and immune-compromised patient groups.